My opinion is that FINRA probably told them the 17th. GNBT
My opinion is that FINRA probably told them the 17th. GNBT changed the terms of the div. Even though it will not affect those that held it would obviously affect those that sold because of the delays. It gives them an opportunity to reevaluate and get back in if they want. The 7 days between record and pay is standard I think.
As a side regarding CMT and Veneto. I’m kind of bipolar on this. My personal natural instinct is to make them pay. Sue them etc. but when I think about their position. They sold assets for GNBT shares. GNBT announces div and excludes them. Whether willingly or forced by BOD vote they waive the div. Now since the public interest in the Co is increasing obviously their stake is decreasing. That alone would piss me off if I were them. Add to that that GNBT announces spinning NGIO. Now you have a smaller stake in a less valuable Co. Lastly GNBT changes the terms of the div and is now giving equity in the spinout (so shareholders are not losing the value of the spinout) but again as restricted shareholder you are excluded. All you can do is watch as your stake decreases and you lose the value of NGIO...Or sell and accept the consequences.
In the case of CMT I can’t say I really blame them. Don’t get me wrong. There is still a part of me that wants them to pay but I don’t see how that would repair the sp or benefit us the shareholders. Maybe GNBT would get some type of settlement but we would not see any part of that.
At this point regarding CMT I’d accept an apology stating “We regret the effect our selling had on the sp but we had to think of our investors first”.
This hurdle all but cleared here is the timeline as I see it
2/17 record date
2/24 pay date
2/25 ex date
GNBT S1 priced and amended by 3/6
Possibly an S1 for NGIO same date or within a week 3/13
NGIO spin by 3/27
GNBT based on value add of NGIO and whatever PRs come out should be ready to uplist by 6/26. Hopefully sooner.
As always just my opinion.
1
Generex Biotechnology Corp. (GNBTQ) Stock Research Links
Scroll down for more posts ▼
Top 10 Most Recent News Articles
A Game-Changer in Proteomics Now ain't this something—eGlint just scooped up the 2026 BioTools Innovator Grand Prize, waving a big ol' $250,000 check around and claiming the biotech spotlight with their swift-moving ProteoNex™ platform. Forget about sticking samples through sluggish labs and waiting an eternity; eGlint's tech is flipping the switch, serving up protein...
Continue Reading
Ever wonder how the cogs in this massive machine called franchising keep turning? It's folks like Richard Huffman who step up to the plate, and his recent election to the International Franchise Association (IFA) Board of Directors is worth a second glance. Huffman: A Franchise Veteran Now, Huffman isn't some rookie in the world of franchising. You see, back in '94, he...
Continue Reading
Plata Rocks the Boat with Rapid Revenue Growth When a digital bank like Plata rakes in $1 billion in Annual Recurring Revenue (ARR) within just 3.5 years, you can't just shrug it off. That's blazing fast by any standard, especially for a financial institution. Emerging from Mexico, this bank's rocket-like ascent is flinging the doors wide open for what's possible in the...
Continue Reading
Ruth E. Carter’s Triumphant Return When a titan of the costume design world circles back to their roots, you know it’s bound to be something special. Ruth E. Carter, who has swapped needles and threads for Oscars (twice, mind you), is making a return to Hampton University, paying homage to the very soil that sowed her artistic seeds. Ain't that a capstone of a career...
Continue Reading
The Real Elbow Grease Behind Cabin Management Ever imagined what it’d take to keep a vacation rental cabin running like a tight ship? Well, Nathan Fitts breaks it down real clear-like. The guy's seen it all in Blue Ridge, Georgia, which isn't just about scenic views—there's serious business brewing behind that cabin charm. More Than Just Fluffing Pillows Turns out,...
Continue Reading
New Kids on the Structured Credit Block? Well, it looks like we're in for a ride with 2GenPen teaming up with Lord Capital to shake up the asset-backed securities (ABS) world. They're strutting their stuff by launching a strategic collaboration to boost credit analysis. Think of it as a power-up for ABS transactions—because nobody loves a murky credit rating. The Heart...
Continue Reading
Unveiling the LB-30 Cyclotron at EANM 2026 Life in nuclear medicine never stands still, and once again, Longevous Beamtech (LBT) is stirring the pot with its brand-new LB-30 series medical cyclotron. They rolled out this high-powered beast at the 39th Annual Congress of the European Association of Nuclear Medicine (EANM 2026) in Vienna. Leaning into the 30 MeV energy...
Continue Reading
A New Contender in the Battle Over Lab Standards Here's what’s heating up in the realm of clinical laboratories: A proposed shift by the Centers for Medicare & Medicaid Services (CMS) that reeks of cutting corners, if you ask the folks at the Association for Diagnostics & Laboratory Medicine (ADLM). They’re banging the drums against CMS's idea to nix the board...
Continue Reading
From Bonds to Ballgames: Hinojosa's Impact Listen up, because this one’s more than just another accolade on a shelf. Noé Hinojosa Jr., a big gun over at TRB Securities, is getting the 2026 Hispanic Business Salute Award, and it's a doozy. Awarded by all the big wigs—UPS, NBC 5, Telemundo 39, and the Dallas Cowboys—this isn't a small pat on the back. It's a full-on...
Continue Reading
CPA Triumphs Yet Again With Bond Savings I'll tell you, the Clean Power Alliance (CPA) just hit the jackpot again. We're talking a $1.4 billion energy prepayment bond deal that locks in a whopping $91.1 million in savings over the next seven years. Not bad, huh? A Closer Look at the Numbers CPA's charm—besides being the top green power supplier in the U.S.—is spinning...
Continue Reading
Top 5 Most Recently Viewed Articles
Understanding the Class Action Against Freeport-McMoRan Recently, a prominent securities law firm announced a class action lawsuit against Freeport-McMoRan Inc. (NYSE: FCX), targeting potential securities fraud as stock prices drastically fell. This lawsuit follows serious allegations concerning the company's safety practices that may have played a part in significant...
Continue Reading
A Shaky Stage in GRAIL's Financial Play When you look at company dramas, GRAIL's latest saga is nothing short of a plot twist worthy of Wall Street headlines. The firm's recent misadventures have landed them in hot water—a securities fraud lawsuit. Investors, if you had a stake in this during the class period, it’s time to wake up and smell the potential losses....
Continue Reading
Introducing Breathe Drops: A Revolutionary Wellness Solution In the ever-evolving world of wellness, Breathe is thrilled to unveil its latest product, Breathe Drops. This unique formula aims to enhance lung health and respiratory wellness by harnessing the power of carefully selected natural ingredients. Designed for individuals seeking natural wellness solutions, Breathe...
Continue Reading
Introduction to aTyr Pharma Inc. aTyr Pharma Inc. (NASDAQ: ATYR) is a biopharmaceutical company focused on developing therapies for serious diseases. The company’s innovative approach strives to improve patient outcomes through its protein therapeutics. Recent Developments In late 2025, aTyr Pharma faced a significant setback when it announced that its Phase 3 study for...
Continue Reading
Understanding EPSO-G's Extraordinary General Meeting EPSO-G, a key player in the energy sector, has taken an important step by convening an Extraordinary General Meeting (EGM). This decision was initiated by the Board of Energy Transmission and Exchange Group EPSO-G, representing a significant moment for the organization and its stakeholders. Purpose of the Meeting The...
Continue Reading